What parents should know about low-level light therapy, the latest research and eye-safety considerations

Why childhood myopia deserves attention

Myopia, commonly known as short-sightedness, makes distant objects appear blurred. It often begins during childhood and may progress as the eyes continue to grow. For parents, the concern is not simply whether a child needs stronger glasses. Higher levels of myopia are associated with a greater risk of developing eye conditions later in life, including retinal complications, glaucoma and myopic macular changes.

The earlier myopia begins, the more time it may have to progress. That is why regular eye examinations and early conversations about myopia management are important—even when a child seems to be seeing well.

What may contribute to the rise in childhood myopia?

Childhood myopia is influenced by a combination of genetic and environmental factors. A family history can increase a child’s likelihood of developing myopia, while lifestyle patterns may also play a role.

Long periods of close-up activities, such as reading, homework and screen use, together with limited time outdoors, are commonly discussed modifiable factors. Outdoor time is an important part of prevention: guidance from myopia experts commonly recommends around one to two hours outdoors each day for school-aged children, where practical and safe.

Healthy visual habits do not replace an eye examination, but they can form part of a wider approach to protecting children’s eye health.

Beyond glasses: understanding myopia management

Glasses help a child see clearly, but ordinary single-vision glasses do not necessarily slow the underlying progression of myopia. Myopia management takes a broader approach: monitoring changes in prescription and, where available, eye growth, while considering suitable strategies to reduce the rate of progression.

Depending on the child’s age, prescription, rate of progression, eye health and family circumstances, an eye-care professional may discuss options such as specially designed spectacle lenses, contact-lens approaches, low-dose atropine or light-based interventions. There is no single option that is right for every child.

What is low-level red-light therapy?

Repeated low-level red-light (RLRL) therapy is an emerging light-based approach being studied for childhood myopia control. In clinical research, children look into a purpose-designed device that delivers a controlled, low-level red-light exposure for short sessions, repeated according to a defined treatment schedule.

The proposed biological effects are still being investigated. Human studies have reported changes in the choroid, a vascular layer beneath the retina, and researchers are exploring how these responses may relate to eye growth and myopia progression. The exact mechanisms are not yet fully established.

The terms photobiomodulation (PBM), LED light therapy and repeated low-level red-light therapy are sometimes used broadly in public discussion. However, they should not be treated as interchangeable descriptions of every light device. Research findings apply to the specific devices, wavelengths, output levels, exposure times and protocols that were studied. They cannot automatically be assumed to apply to all PBM-LED products.

What does the latest research say about effectiveness?

Recent evidence is encouraging. A 2026 systematic review and meta-analysis in BMC Ophthalmology included 14 randomised controlled trials involving 1,942 children and adolescents. Compared with single-vision spectacles, the review reported less axial length elongation and slower refractive progression in the RLRL groups over follow-up periods of up to 12 months.

Another 2026 systematic review in Clinical & Experimental Ophthalmology included 28 randomised trials and 3,573 participants. It reported improvements in refractive outcomes and choroidal thickness at 12 months, while noting that certainty differed between outcomes and that longer-term evidence is still needed.

These findings suggest that RLRL may become an additional option in the myopia-management conversation. They do not mean that every child will respond in the same way, or that results from one device or protocol can be applied to another.

Safety matters: what should parents ask?

Safety should be considered alongside effectiveness. Published trials and reviews have generally reported a favourable short-term tolerability profile under controlled study conditions, with many reported effects described as mild or temporary. However, the evidence does not establish that all red-light devices are equally safe, or that long-term risks have been fully resolved.

Recent reviews have highlighted the need for longer follow-up, consistent device measurements and careful retinal monitoring. Published literature has also discussed occasional retinal imaging changes and case reports that reinforce why device-specific safety assessment matters. A reassuring result from one clinical trial should not be interpreted as a blanket safety guarantee for every product.

Before considering light therapy, parents should discuss these questions with a qualified eye-care professional:

• Is this exact device supported by clinical evidence for childhood myopia management?
• Are its wavelength, light output, exposure time and treatment protocol clearly specified?
• Has the device undergone appropriate safety and regulatory assessment for its intended use in children?
• What baseline eye examination and follow-up monitoring are recommended?
• What symptoms should prompt the family to stop treatment and seek review?

Parents should not improvise treatment using ordinary red-light lamps, home LED devices or products that have not been designed and assessed for ocular use. A child should follow only the instructions and treatment schedule prescribed for the specific device by an appropriately qualified professional.

Monitoring is part of responsible myopia care

Myopia management is an ongoing process, not a one-time treatment. Regular reviews allow the eye-care professional to check the child’s prescription, assess eye growth where appropriate, review adherence and look for any changes that may require the management plan to be adjusted.

Families should report new or unusual symptoms promptly, including persistent afterimages, blurred vision, visual distortion, discomfort or any noticeable change in vision. The clinician can advise whether treatment should be paused and whether further examination is needed.

Every child’s needs are different. The most appropriate plan is one that balances the child’s clinical profile, the available evidence, safety considerations and the family’s ability to follow up consistently.

A brighter approach begins with informed choices

New light-based approaches are expanding the options being studied for childhood myopia management. Repeated low-level red-light therapy has produced promising results in clinical research, but responsible use depends on the exact device and protocol, careful patient selection and ongoing professional monitoring.

For parents, the most useful first step is a comprehensive eye examination and a discussion about the rate of myopia progression. With early awareness, healthy visual habits and an individually guided management plan, families can make better-informed decisions to support their children’s eye health.

Medical note

Medical note: Light-based myopia management is not suitable for every child and should only be considered under the guidance of an appropriately qualified eye-care professional. Evidence and safety findings are device- and protocol-specific. This article is for general education and does not replace a comprehensive eye examination, personalised clinical advice or ongoing monitoring.

References

1. American Academy of Ophthalmology – Myopia Control in Children (2026). https://www.aao.org/eye-health/glasses-contacts/myopia-control-in-children
2. Liu et al. (2026), Efficacy of repeated low-level red-light therapy for myopia management in children and adolescents: a systematic review and meta-analysis, BMC Ophthalmology. https://pubmed.ncbi.nlm.nih.gov/41680682/
3. Duration-Dependent Efficacy and Clinical Safety of Repeated Low-Level Red-Light Therapy for Paediatric Myopia: A Systematic Review and Meta-Analysis (2026). https://pubmed.ncbi.nlm.nih.gov/41846466/
4. Repeated low-level red-light therapy for childhood myopia: Efficacy, mechanisms, rebound effects, safety boundaries, and clinical standardization (2026). https://pubmed.ncbi.nlm.nih.gov/42349599/
5. Safety of repeated low-level red-light therapy for myopia: A systematic review (2024). https://doi.org/10.1016/j.apjo.2024.100124
6. European Society of Ophthalmology / International Myopia Institute – Myopia management algorithm. https://pmc.ncbi.nlm.nih.gov/articles/PMC11295429/